National Statistician and Civil Registrar General Usec. Claire Dennis S. Mapa (2nd from left) leading the distribution of ...

The ENLIGHTEN program consists of two Phase 3 clinical trials, ENLIGHTEN 1 and ENLIGHTEN 2, to evaluate the efficacy and safety of LYR-210 for the treatment of CRS. While the ENLIGHTEN 2 trial met ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic ...

Lyra Therapeutics has lost >90% of its value since announcing the failed ENLIGHTEN-1 trial. Click here to find out why I rate ...

AML patientsMipletamig combination enables rare pathway to transplant in a previously ineligible unfit patientNo dose-limiting toxicities observed among ...

The first of the selected abstracts came from Wolfgang Merkt, who presented an update on a patient who originally received third-generation CD19-CAR-T ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD). This and other cell-depleting approaches ...

Background Over the last few years, there has been increasing attention to the involvement of the central nervous system in Duchenne muscular dystrophy (DMD). The aim of this study was to assess the ...

Alfred L. Garfall, MD, provided a deep dive into the phase 2 BMT CTN 1902 trial of ide-cel in multiple myeloma after ...

Much of the rail infrastructure is outdated, having been built over a century ago with little regard for even incremental ...

Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New England Journal of Medicine THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced ...

Call it abandonment, anxiety, or just latent stupidity. The messy goo of feelings and fuzzy notions behind Australia’s most injudicious strategic decision is yielding its nasty harvest. Conceived by ...